More good news for private biotechs

December 1, 2014 Guest Contributor

SarDemy_Cropped_DSC7959Guest post by Sara Jane Demy, CEO, Demy-Colton Life Science Advisors

Polaris Partners joins the parade of new biotech funds launched in 2014 with a USD 450 million fund which exceeds the USD 400 million number they filed with the SEC last summer. Polaris joins Arch, Venrock, Versant and Sofinnova, among others, who have launched funds of similar size in 2014. See this article in FierceBiotech.

These new funds will bring a welcome surge of new private capital to innovative biotechs. How will it be deployed and will it be enough to sustain early-stage development at a time when drug development costs are soaring? Our Wednesday plenary panel at Biotech Showcase™ will discuss these topics and others as they contemplate the next five years of private investment in the biopharmaceutical industry.

Original post on LinkedIn.Demy-Colton_logoOL_Vertical_cmyk_20141120


Previous Article
The complexity of immuno-oncology trials
The complexity of immuno-oncology trials

The value of developing an immunotherapy has grown over the past few years – as science and technology has ...

Next Article
Objectives of translational medicine

One of the hardest parts of translational medicine is melding the two objectives of the academic institutio...